Mayne Pharma Group Limited

CHIA:MYX Stock Report

Market Cap: AU$369.7m

Mayne Pharma Group Valuation

Is MYX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of MYX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate MYX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate MYX's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MYX?

Key metric: As MYX is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for MYX. This is calculated by dividing MYX's market cap by their current revenue.
What is MYX's PS Ratio?
PS Ratio1x
SalesAU$388.40m
Market CapAU$369.67m

Price to Sales Ratio vs Peers

How does MYX's PS Ratio compare to its peers?

The above table shows the PS ratio for MYX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average11.7x
SNT Syntara
20x1.7%AU$115.3m
VLS Vita Life Sciences
1.4xn/aAU$111.9m
IDT IDT Australia
3.2xn/aAU$45.1m
RCE Recce Pharmaceuticals
22.1x-13.1%AU$111.3m
MYX Mayne Pharma Group
1x9.3%AU$369.7m

Price-To-Sales vs Peers: MYX is good value based on its Price-To-Sales Ratio (1x) compared to the peer average (11.7x).

Price to Sales Ratio vs Industry

How does MYX's PS Ratio compare vs other companies in the AU Pharmaceuticals Industry?

18 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.4.7x45.6%
MYX Mayne Pharma Group
 1x9.3%US$229.89m
PBP Probiotec
1.1x6.7%US$160.13m
VLS Vita Life Sciences
1.4xn/aUS$69.56m
MYX 1.0xIndustry Avg. 4.7xNo. of Companies17PS01224364860+
18 CompaniesEstimated GrowthMarket Cap
Industry Avg.4.7x32.8%
MYX Mayne Pharma Group
 1x111.4%US$229.89m
No more companies

Price-To-Sales vs Industry: MYX is good value based on its Price-To-Sales Ratio (1x) compared to the Australian Pharmaceuticals industry average (4.7x).

Price to Sales Ratio vs Fair Ratio

What is MYX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MYX PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1x
Fair PS Ratio3.5x

Price-To-Sales vs Fair Ratio: MYX is good value based on its Price-To-Sales Ratio (1x) compared to the estimated Fair Price-To-Sales Ratio (3.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst MYX forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentAU$4.60
AU$6.10
+32.6%
2.4%AU$6.25AU$5.95n/a2
Jan ’26AU$4.94
AU$6.10
+23.5%
2.4%AU$6.25AU$5.95n/a2
Dec ’25AU$5.13
AU$6.09
+18.7%
2.6%AU$6.25AU$5.93n/a2
Nov ’25AU$4.44
AU$6.09
+37.2%
2.6%AU$6.25AU$5.93n/a2
Oct ’25AU$4.74
AU$6.09
+28.5%
2.6%AU$6.25AU$5.93n/a2
Sep ’25AU$5.22
AU$6.09
+16.7%
2.6%AU$6.25AU$5.93n/a2
Aug ’25AU$4.22
AU$6.89
+63.3%
2.9%AU$7.09AU$6.69n/a2
Jul ’25AU$4.64
AU$6.89
+48.5%
2.9%AU$7.09AU$6.69n/a2
Jun ’25AU$5.02
AU$6.89
+37.3%
2.9%AU$7.09AU$6.69n/a2
May ’25AU$6.78
AU$7.04
+3.8%
4.9%AU$7.38AU$6.69n/a2
Apr ’25AU$7.23
AU$7.04
-2.6%
4.9%AU$7.38AU$6.69n/a2
Mar ’25AU$6.80
AU$7.04
+3.5%
4.9%AU$7.38AU$6.69n/a2
Feb ’25AU$5.26
AU$4.65
-11.6%
18.3%AU$5.50AU$3.80n/a2
Jan ’25AU$6.14
AU$4.65
-24.3%
18.3%AU$5.50AU$3.80AU$4.942
Dec ’24AU$5.48
AU$3.90
-28.8%
2.6%AU$4.00AU$3.80AU$5.132
Nov ’24AU$3.55
AU$3.50
-1.4%
8.6%AU$3.80AU$3.20AU$4.442
Oct ’24AU$3.26
AU$3.24
-0.6%
17.3%AU$3.80AU$2.68AU$4.742
Sep ’24AU$3.37
AU$4.12
+22.1%
7.7%AU$4.43AU$3.80AU$5.222
Aug ’24AU$4.80
AU$4.12
-14.3%
7.7%AU$4.43AU$3.80AU$4.222
Jul ’24AU$4.42
AU$4.12
-6.9%
7.7%AU$4.43AU$3.80AU$4.642
Jun ’24AU$3.78
AU$4.12
+8.9%
7.7%AU$4.43AU$3.80AU$5.022
May ’24AU$4.11
AU$3.65
-11.2%
4.1%AU$3.80AU$3.50AU$6.782
Apr ’24AU$3.78
AU$4.03
+6.7%
13.8%AU$4.80AU$3.50AU$7.233
Mar ’24AU$3.92
AU$4.03
+2.9%
13.8%AU$4.80AU$3.50AU$6.803
Feb ’24AU$3.04
AU$5.20
+71.2%
30.5%AU$7.40AU$2.99AU$5.264
Jan ’24AU$4.00
AU$5.50
+37.5%
27.8%AU$7.40AU$3.40AU$6.144
Analyst Price Target
Consensus Narrative from 2 Analysts
AU$6.17
Fair Value
25.4% undervalued intrinsic discount
2
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/21 00:47
End of Day Share Price 2025/01/21 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Mayne Pharma Group Limited is covered by 10 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Russell WrightBarclay Pearce Capital Pty Limited
John HesterBell Potter
William DunlopBofA Global Research